# Zennova Pharmaceuticals Group

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zennova-pharmaceuticals-group

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.zennova.com
- Latest round: Series A (Aug 23, 2021)
- Investors on record: 3

## About

Based in Chengdu, China, and founded in 2018. Zennova Pharmaceuticals Group is a pharmaceutical company that focuses on the R&D, manufacturing, and sales of new drugs. The company has research and development, and production bases in Chengdu, and USA. The Chengdu production base passed the certifications, such as US FDA, EU EMA, and China cGMP standards. Dahai Guo, The company's chairman of the board and chief executive officer, has served as chairman and CEO over 7 companies, such as PuraCap pharceutical LLC, Humanwell USA LLC. In July 2023, Zennova Pharmaceuticals Group raised approximately CNY 100 million in series B funding from new investor HBM Protections. 

The company provides ophthalmic drugs, antitumor drugs, antiviral drugs, and cardiovascular drugs. It has technology platform, Liquipuls, integrates with Pulsed Microdialysis (PMD) analysis, microsphere coating, slow and controlled release, nanoparticle technology, optimised delivery technology. Its products are sold to American, Europe, Japan and Southeast Asia.  

The company will complete the production base's interior decoration and equipment installation in September 2023, and start the technical transfer of the FDA-approved series of drugs in the fourth quarter.

## Funding rounds

- Series A, Aug 23, 2021 — DYEE Capital, E-town Sun Fund
- Angel, Dec 10, 2018 — Sichuan Venture Capital

## Investors

- Sichuan Venture Capital (https://capitalatlas.ai/funds/sichuan-venture-capital) — Angel
- DYEE Capital (https://capitalatlas.ai/funds/dyee-capital) — Series A
- E-town Sun Fund (https://capitalatlas.ai/funds/e-town-sun-fund) — Series A